Mealey's (August 10, 2022, 4:16 PM EDT) -- ATLANTA — A federal district court did not err in dismissing a shareholder’s federal securities law claims against a medical technology company and others, alleging that the defendants misrepresented the markets for the company’s nerve graft product because the defendants’ alleged misstatements were forward-looking and protected by the safe harbor provision of the Private Securities Litigation Reform Act of 1995 (PSLRA), an 11th Circuit U.S. Court of Appeals panel ruled Aug. 1 in affirming....